Monthly Archives: September 2011
By Ben Comer | Published: September 20, 2011
Amid the flurry of cost-cutting proposals aimed at guiding the Joint Select Committee on Deficit Reduction’s (Super Committee) budgetary blade, the Obama Administration has now weighed in with a proposal to cut $248 billion from Medicare spending over ten years, and $73 billion in Medicaid and other health-related spending. The Obama plan, which would increase [...]
By Jennifer Ringler | Published: September 19, 2011
Pharmaceutical Executive recently spoke with David Vance, Senior Director of the Compliance Counsel at Noven Pharmaceuticals, about the birth of Expanded Access Programs and the role patient advocacy groups can play in shaping those programs.
By Ben Comer | Published: September 14, 2011
On the heels of President Obama’s unveiling of the American Jobs Act, Synta Pharmaceuticals CEO Safi Bahcall – who attended the president’s jobs speech last week as a special guest of House Speaker John Boehner (R-OH) – spoke to Pharmaceutical Executive about the role of government in supporting innovation.
By Guest Blogger | Published: September 13, 2011
By Tom Norton As the country struggles with the current economic malaise, and the pharmaceutical industry enters into yet another difficult quarter of “trying to make the numbers,” one matter that I doubt many Rx execs are thinking about today is the HCR Taxman. That’s too bad. They probably should. That’s because he’s coming for the [...]
By Ben Comer | Published: September 8, 2011
Following on Gov. Rick Perry’s call for “some provocative language in this country” during last week’s GOP debate at the Reagan Library, Rep. Ron Paul (R-TX) said federal drug regulations “don’t take good care of us.”